海南海药（000566）公告，2024年营业收入为9.91亿元，同比下降33.00%。归属于上市公司股东的净亏 损15.25亿元，去年同期净亏损1.06亿元。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

Financial Performance - The company's operating revenue for 2024 was CNY 990,701,458.53, a decrease of 33.00% compared to CNY 1,478,580,692.25 in 2023[21]. - The net profit attributable to shareholders for 2024 was a loss of CNY 1,525,200,923.81, compared to a loss of CNY 106,488,625.88 in 2023[21]. - The net cash flow from operating activities for 2024 was a negative CNY 17,552,031.29, down from a positive CNY 103,548,849.10 in 2023[21]. - The basic earnings per share for 2024 was -CNY 1.1756, compared to -CNY 0.0821 in 2023[21]. - The company's diluted earnings per share for 2024 is -1.1756 CNY, a significant decline from 0.0081 CNY in 2023[22]. - The weighted average return on equity for 2024 is -117.88%, down from 0.49% in 2023, indicating severe financial distress[22]. - Total assets decreased by 17.01% to 6,113,528,499.69 CNY in 2024 from 7,366,534,916.00 CNY in 2023[22]. - Net assets attributable to shareholders fell by 74.53% to 525,286,982.84 CNY in 2024 compared to 2,062,448,256.73 CNY in 2023[22]. - The company reported a total of -330,545,543.90 CNY in non-recurring losses for 2024, compared to 303,697,658.75 CNY in 2023[28]. - The company reported a net profit of -876,808,463.42 yuan for the 2024 fiscal year[152]. - The company reported an unallocated profit of -¥924,917,125.03, resulting in no profit available for distribution to shareholders[153]. Strategic Initiatives - Future outlook includes addressing operational risks and implementing measures to improve financial performance[5]. - The company is focusing on new product development and market expansion strategies to enhance growth prospects[5]. - The report indicates a need for strategic adjustments in response to declining revenues and profitability[21]. - The company aims to enhance its competitive edge by integrating resources and increasing R&D investment for new product development[51]. - The company is actively involved in the development of new drug intermediates, such as 7-ANCA and 4-AA, which are essential for the production of antibiotics like Cefoperazone and Meropenem[45]. - The company is focused on expanding its market reach through strategic partnerships and acquisitions in the pharmaceutical sector, aiming for growth in both domestic and international markets[46]. - The company is expanding its e-commerce business and leveraging the Hainan Free Trade Port policy to introduce foreign health products, aiming to increase market sales significantly[102]. - The company is currently fulfilling its commitments regarding competition and related transactions as per the acquisition report[187]. Research and Development - The company has accelerated its R&D efforts, achieving significant progress in product consistency evaluation, with 15 formulation products either approved or deemed approved[34]. - Research and development expenses amounted to ¥123,609,867.80, a decrease of 5.49% from ¥130,790,360.71 in the previous year[53]. - R&D investment amounted to ¥123,609,867.80 in 2024, a decrease of 5.49% from ¥130,790,360.71 in 2023, while the proportion of R&D investment to operating revenue increased from 8.85% to 12.48%[74]. - The company completed Phase II clinical trials for the anti-fibrosis drug Fluorofenidone, which is expected to expand the chronic disease drug pipeline[73]. - The company has a diverse pipeline with multiple drugs in various stages, including 5 drugs that have passed consistency evaluations and are awaiting market release[49]. Market and Sales Performance - The pharmaceutical segment generated ¥794,341,106.73, accounting for 80.18% of total revenue, reflecting a 38.06% decline from ¥1,282,384,086.12 in the previous year[54]. - Domestic sales amounted to ¥930,914,486, reflecting a significant year-on-year growth of 36.90%[57]. - The distribution business generated ¥536,383,638, up 53.83% compared to the previous year[57]. - The total sales volume of pharmaceutical products decreased by 36.47% to 114,557,690.02 units, primarily due to policy changes and reduced demand[58]. - The company achieved a 19.38% year-on-year increase in warehouse revenue, with overall warehouse utilization at 62% and cold storage utilization at 100%[38]. Governance and Compliance - The company emphasizes the importance of maintaining accurate financial reporting and compliance with regulatory standards[5]. - The company has established a high-level R&D team and optimized its talent structure, with 26 high-level talents recognized by Hainan Province[39]. - The company has established an EHS management system to comply with national safety and environmental regulations, aiming for sustainable development[106]. - The company has implemented a value enhancement plan and is committed to improving its governance structure in accordance with relevant laws and regulations[110]. - The company has not encountered any significant internal control deficiencies during the reporting period[156]. Environmental Responsibility - The company has complied with environmental protection policies and standards, ensuring that wastewater and waste gas emissions meet regulatory requirements[163]. - The company has invested significantly in environmental protection, ensuring that all pollutants are discharged within the standard limits, with no exceedances reported[175]. - The company conducts daily self-monitoring of wastewater parameters, including pH, COD, and ammonia nitrogen, with all results meeting the required limits[176]. - The company has established an emergency response plan for environmental incidents, which has been filed with the local environmental authority[178]. - The company has maintained a zero-incident record for environmental violations and pollutant exceedances throughout the reporting period[175]. Leadership and Management Changes - The company has a management team with a mix of experienced and newly appointed members, ensuring continuity and fresh perspectives[120]. - The company is preparing for future growth with a refreshed leadership team and strategic appointments[121]. - The company held its first temporary shareholders' meeting on April 2, 2024, with a participation rate of 32.37%[117]. - The company plans to hold its third temporary shareholders' meeting on December 18, 2024, with a participation rate of 31.81% expected[117]. - The company is focused on maintaining stability in its leadership as it approaches the next fiscal year[120].

创新药概念震荡拉升，海南海药（000566）涨停，一品红（300723）、泓博医药（301230）、科兴制 药、海正药业（600267）、中源协和（600645）等跟涨。 暗盘资金正涌入这些股票，点击速看>>> ...

截至本公告披露日，上述辞职人员未持有公司股份。王建鹏先生在任职期间 勤勉尽责，公司及董事会对王建鹏先生在任职期间为公司所作的贡献表示衷心感 谢。 证券代码：000566 证券简称：海南海药 公告编号：2025-022 海南海药股份有限公司 关于公司高级管理人员辞职的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"或"海南海药"）董事会于 2025 年 4 月 7 日收到王建鹏先生的辞职报告。王建鹏先生因工作调整的原因申请 辞去公司销售总监职务。辞职后，王建鹏先生仍在海南海药股份有限公司子公司 继续担任其他职务，其辞职报告自送达公司董事会之日起生效。 特此公告 海南海药股份有限公司 董 事 会 二〇二五年四月八日 ...

Core Viewpoint - The board of directors of Hainan Haiyao Co., Ltd. held a meeting on March 27, 2025, to discuss and approve several key resolutions, including the election of a new non-independent director, the appointment of a new general manager, and the provision of guarantees for subsidiaries [1][2][3]. Group 1: Board Resolutions - The board approved the election of Tian Yong as a non-independent director, following the retirement of Wang Junhong due to retirement [1][2]. - Tian Yong was also appointed as the general manager of the company, with his term starting from the board's approval [2]. - The board agreed to provide guarantees for its subsidiaries, with a total guarantee amount of 174 million yuan, to support their operational needs [2][3]. Group 2: Upcoming Shareholder Meeting - The board resolved to convene the second extraordinary general meeting of shareholders on April 16, 2025, to review the matters discussed in the board meeting [3]. Group 3: Candidate Profile - Tian Yong, born in 1981, graduated from China Pharmaceutical University in 2003 and has held various positions in Tianjin Huajin Pharmaceutical Co., Ltd. before joining Hainan Haiyao [4][5]. - He currently does not hold any shares in the company and has no conflicts of interest with major shareholders or other board members [5].

证券代码：000566 证券简称：海南海药 公告编号：2025-019 海南海药股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：本次股东大会为 2025 年第二次临时股东大会 2、股东大会的召集人：公司第十一届董事会。公司第十一届董事会第二十三次会 议于2025年3月27日审议通过了《关于召开2025年第二次临时股东大会的议案》。 3、会议召开的合法、合规性：本次股东大会的召开程序符合有关法律、行政法规、 部门规章、规范性文件和《公司章程》等的规定。 4、会议召开的日期、时间： 现场会议召开时间：2025年4月16日下午15：00 网络投票时间：2025年4月16日 （1）通过深圳证券交易所交易系统进行网络投票的时间为：2025年4月16日 9：15～9：25，9：30～11：30和13：00～15：00； 5、会议的召开方式：本次股东大会采用现场表决与网络投票相结合的方式召开。 公 司 将 通 过 深 圳 证 券 交 易 所 交 易 系 统 和 互 联 网 ...

海南海药股份有限公司 第十一届董事会第二十三次会议决议公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"或"海南海药"）第十一届董事 会第二十三次会议于 2025 年 3 月 27 日以通讯表决方式召开。本次会议于 2025 年 3 月 25 日以电子邮件等方式送达了会议通知及文件。会议应到董事 8 人，实到董 事 8 人。本次会议的召开符合《公司法》和《公司章程》有关规定。经与会董事 认真审议，表决通过了如下议案： 一、审议通过了《关于选举公司第十一届董事会非独立董事的议案》 证券代码：000566 证券简称：海南海药 公告编号：2025-018 三、审议通过了《关于公司为控股子公司提供担保的议案》 公司为保证各子公司的经营和发展需要，满足生产经营活动对流动资金的需 求，公司拟为以下控股子公司提供担保，担保期限为自股东大会审议通过之日起 三年。对各子公司提供担保额度如下： 王俊红女士因退休原因申请辞去公司董事、总经理及董事会专门委员会相关 职务。为保证公司董事会各项工作的顺利开展，根据《公司法》《深圳证券交易 所上市公 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-020 海南海药股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别风险提示：公司及控股子公司对外担保（均系公司对控股子公司或控股 子公司之间的担保）总额超过最近一期经审计净资产 100%；对资产负债率超过 70% 的单位担保（均系公司对控股子公司或控股子公司之间的担保）金额超过公 司最近一期经审计净资产 50%。公司不存在对合并报表外单位的担保金额，达到 或超过最近一期经审计净资产 30%的情况，敬请广大投资者注意担保风险。 一、概述 海南海药股份有限公司（以下简称"公司"）为保证各子公司的经营和发展 需要，满足生产经营活动对流动资金的需求，公司拟为以下控股子公司提供担保， 担保期限为自股东大会审议通过之日起 3 年。对各子公司提供担保额度如下： | 序号 | 担保方 | 被担保公司 | 直接或间接 | 担保金额 | | --- | --- | --- | --- | --- | | | | | 持股比例 | （万元） | | 1 | 海南海药股份 有 ...

本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"或"海南海药"）的控股子公司 重庆天地药业有限责任公司（以下简称"天地药业"）于近日收到重庆市农业农 村委员会颁发的《兽药生产许可证》和《兽药 GMP 证书》。现将有关情况公告如 下： 证券代码：000566 证券简称：海南海药 公告编号：2025-021 海南海药股份有限公司关于控股子公司 获得《兽药生产许可证》和《兽药 GMP 证书》的公告 一、证书基本信息 （一）《兽药生产许可证》 证书编号：兽药生产证字 23047 号 有效期：2025 年 03 月 18 日至 2030 年 03 月 17 日 （二）《兽药 GMP 证书》 证书编号：(2025)兽药 GMP 证字 23001 号 有效期：2025 年 03 月 18 日至 2030 年 03 月 17 日 二、对公司的影响及风险提示 天地药业获得《兽药生产许可证》和《兽药 GMP 证书》，标志着相关生产 条件已满足《兽药生产质量管理规范（2020 年修订）》规定要求，为公司当前 海南海药股份有限公司 董 事 会 1 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-017 海南海药股份有限公司 海南海药股份有限公司（以下简称"公司"）全资子公司海口市制药厂有限 公司近日获得国家药品监督管理局核准签发的化学药品"罗沙司他胶囊"的《药 品注册证书》。现将相关情况公告如下： 一、药品基本情况 1、药品名称：罗沙司他胶囊 剂型：胶囊 规格：20mg、50mg 关于子公司获得罗沙司他胶囊药品注册批件的公告 受理号：CYHS2303051、CYHS2303052 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 适应症：本品适用于慢性肾脏病(CKD)引起的贫血，包括透析及非透析患者。 药品上市许可持有人：海口市制药厂有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 2、药品的其他相关情况 罗沙司他(Roxadustat)胶囊是小分子低氧诱导因子脯氨酰羟化酶抑制剂 （HIF-PHI）类治疗肾性贫血的药物。罗沙司他通过模拟脯氨酰羟化酶（PH）的 底物之一酮戊二酸来抑制 PH 酶，影响 PH 酶在维 ...